Menu
Not yet recruiting NCT07373106

Short-term Effects of Broccoli-derived Glucoraphanin on Recovery From Eccentric Muscle Damage

No phase Interventional Healthy

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: broccoli powder consumption, Placebo (no broccoli-derived bioactives).
Who it may be relevant to
Registry conditions: Healthy. Basic parameters: 18 years — 35 years · Male.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

SHORT-TERM EFFECTS OF BROCCOLI-DERIVED GLUCORAPHANIN ON RECOVERY FROM ECCENTRIC MUSCLE DAMAGE: A DOUBLE-BLIND RANDOMIZED CROSSOVER STUDY

Overview

Eccentric exercise induces muscle damage and delay functional recovery. Broccoli-derived glucoraphanin (a sulforaphane precursor that activates Nrf2 defenses) may aid repair; however, its short-term effects in humans remains unknown. This study aims to evaluate whether short-term supplementation with broccoli-derived glucoraphanin will improve recovery from exercise-induced muscle damage. In a randomized, double-blind, placebo-controlled crossover design, fifteen participants will consume either high-glucoraphanin broccoli powder (320 μg) or placebo for one week, followed by elbow flexor eccentric exercise and continued supplementation. Strength, soreness, creatine kinase (CK), range of motion (ROM), arm girths, and ultrasound-assessed muscle and tendon morphology will be measured at baseline, immediately post-exercise, and at 48 and 96 hours post-exercise.

Interventions

  • Dietary supplement broccoli powder consumption
    Participants underwent two separate sessions of muscle-damaging exercise targeting the elbow flexors: (1) following seven days of broccoli powder consumption (condition X), and (2) following an equivalent placebo regimen (condition Y). The broccoli supplementation consisted of 10 g of broccoli powder \[a freeze-dried glucoraphanin-rich broccoli powder (99.5% broccoli and 0.5% mustard seed)\] dissolved in 125 mL of boiling water, providing 320 μg of glucoraphanin per serving. It was consumed when
  • Dietary supplement Placebo (no broccoli-derived bioactives)
    The placebo powder, matched in appearance and preparation, contained no broccoli-derived bioactives.

Primary outcome measures

  • Peak torque, Nm/s [Time frame: At baseline, immediately post-exercise, and at 48 hours, and at 96 hours post-exercise.]
  • Range of motion, degree [Time frame: At baseline, immediately post-exercise, and at 48 hours, and at 96 hours post-exercise.]
  • Arm girth, mm [Time frame: At baseline, immediately post-exercise, and at 48 hours, and at 96 hours post-exercise.]
Secondary outcome measures (2)
  • Soreness, points [Time frame: At baseline, immediately post-exercise, and at 48 hours, and at 96 hours post-exercise.]
  • Creatine kinase, IU/L [Time frame: At baseline, immediately post-exercise, and at 48 hours, and at 96 hours post-exercise.]

Eligibility criteria

Inclusion criteria

  • no resistance training experience in the past 6 months, no arm injuries in the past 2 years, no illnesses in the month prior to data collection, and no known allergies to broccoli or other cruciferous vegetables.

Exclusion criteria

  • incomplete participation.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Basic science

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07373106 · MNLKIN(M)-2024-574

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗